Literature DB >> 16280973

Good laboratory practices for waived testing sites: survey findings from testing sites holding a certificate of waiver under the clinical laboratory improvement amendments of 1988 and recommendations for promoting quality testing.

Devery Howerton1, Nancy Anderson, Diane Bosse, Sharon Granade, Glennis Westbrook.   

Abstract

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), simple, low-risk tests can be waived and performed with no routine regulatory oversight in physicians' offices and various other locations. Since CLIA was implemented, waived testing has steadily increased in the United States. Surveys conducted during 1999-2004 by the Centers for Medicare & Medicaid Services and studies funded by CDC during 1999-2003 evaluated testing practices in sites holding a CLIA Certificate of Waiver (CW). Although study findings indicate CW sites generally take measures to perform testing correctly, they raise quality concerns about practices that could lead to errors in testing and poor patient outcomes. These issues are probably caused, in part, by high personnel turnover rates, lack of understanding about good laboratory practices, and inadequate training. This report summarizes study findings and provides recommendations developed by the Clinical Laboratory Improvement Advisory Committee for conducting quality waived testing. These recommendations include considerations before introducing waived testing, such as management responsibility for testing, regulatory requirements, safety, physical and environmental requirements, benefits and costs, staffing, and documentation. They also cover good laboratory practices for the three phases of testing: 1) before testing (test ordering and specimen collection), 2) during testing (control testing, test performance, and result interpretation and recording), and 3) after testing (result reporting, documentation, confirmatory testing, and biohazard waste disposal). They are intended to be used by those who would benefit from improving their knowledge of good laboratory practices. Continued monitoring of waived testing, with a focus on personnel education and training, is needed to improve practices and enhance patient safety as waived testing continues to increase.

Entities:  

Mesh:

Year:  2005        PMID: 16280973

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  7 in total

1.  HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Authors:  Bernard M Branson
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

2.  The Role of Pharmacists and Pharmacy Education in Point-of-Care Testing.

Authors:  James P Kehrer; Deborah E James
Journal:  Am J Pharm Educ       Date:  2016-10-25       Impact factor: 2.047

3.  Impact of Rapid Molecular Respiratory Virus Testing on Real-Time Decision Making in a Pediatric Emergency Department.

Authors:  Daniel T Rogan; Mohit S Kochar; Samuel Yang; James V Quinn
Journal:  J Mol Diagn       Date:  2017-03-22       Impact factor: 5.568

4.  Appropriateness of tumor marker request: a case of study.

Authors:  Massimo Gion; Chiara Trevisiol; Aline S C Fabricio
Journal:  Ann Transl Med       Date:  2017-07

5.  HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.

Authors:  Paul J Weidle; Shirley Lecher; Linda W Botts; LaDawna Jones; David H Spach; Jorge Alvarez; Rhondette Jones; Vasavi Thomas
Journal:  J Am Pharm Assoc (2003)       Date:  2014 Sep-Oct

Review 6.  Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests.

Authors:  Marwan M Azar; Marie L Landry
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

Review 7.  Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future.

Authors:  Nancy E Cornish; Nancy L Anderson; Diego G Arambula; Matthew J Arduino; Andrew Bryan; Nancy C Burton; Bin Chen; Beverly A Dickson; Judith G Giri; Natasha K Griffith; Michael A Pentella; Reynolds M Salerno; Paramjit Sandhu; James W Snyder; Christopher A Tormey; Elizabeth A Wagar; Elizabeth G Weirich; Sheldon Campbell
Journal:  Clin Microbiol Rev       Date:  2021-06-09       Impact factor: 50.129

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.